Cardiff Oncology, Inc.
CRDF
$1.74
-$0.07-3.87%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
3/19/2026
-
Globe Newswire
3/4/2026
-
MarketBeat
3/4/2026
-
MarketBeat
3/2/2026
-
MarketBeat
3/2/2026
-
Ticker Report
2/27/2026
-
MarketBeat
2/26/2026
-
Globe Newswire
2/26/2026
-
TipRanks Financial Blog
2/26/2026
-
MarketBeat
2/25/2026
-
Ticker Report
2/25/2026
-
MarketBeat
2/25/2026
-
The Fly
2/25/2026
-
TipRanks Financial Blog
Analysts Are Bullish on These Healthcare Stocks: Cardiff Oncology (CRDF), AbCellera Biologics (ABCL)
2/25/2026
-
TipRanks Financial Blog
2/24/2026
-
Zolmax
2/24/2026
-
MarketBeat
2/24/2026
-
Globe Newswire
2/19/2026
-
Globe Newswire
2/19/2026
-
MarketBeat
2/5/2026
-
MarketBeat
2/5/2026
-
MarketBeat
1/29/2026
-
Simply Wall St
1/28/2026
-
GuruFocus
1/28/2026
-
Benzinga
1/28/2026
-
TipRanks Financial Blog
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Tuesday, February 24, 2026
Period Date
Wednesday, December 31, 2025
Next Filing
Week of May 4 and 8 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
858 952 7570
Address
11055 Flintkote Avenue
San Diego, CA 92121
San Diego, CA 92121
Country
Year Founded
Business Description
Sector
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral...
more